Esperion Therapeutis.Inc. buy HC Wainwright
Summary
This prediction is currently active. The BUY prediction by HC_Wainwright shows slight gains of 6.54%. This prediction currently runs until 08.05.25. The prediction end date can be changed by HC_Wainwright at any time. HC_Wainwright has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w |
---|---|
Esperion Therapeutis.Inc. | 6.330% |
iShares Core DAX® | -0.383% |
iShares Nasdaq 100 | 1.248% |
iShares Nikkei 225® | 0.525% |
iShares S&P 500 | 0.640% |
Comments by HC_Wainwright for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by HC_Wainwright for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
25.03.24
25.03.25
17.05.24
Esperion Therapeutis.Inc.
28.02.24
28.02.25
17.05.24
Esperion Therapeutis.Inc.
13.11.23
13.11.24
17.05.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
17.05.24
Esperion Therapeutis.Inc.
06.03.23
06.03.24
07.03.24